The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Impact of impaired glutamine/glutamate metabolic axis on osteoclast activation in multiple myeloma
Nicola Giuliani, MD, PhD, University of Parma, Parma, Italy, discusses the impact of impaired glutamine/glutamate metabolism on osteoclast formation and bone destruction, commenting on in vitro data showing that high levels of glutamate in the bone microenvironment stimulate osteoclast signaling and subsequent osteoclast activation. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
